Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia

by Business Wire • 2025/06/03 • 0 Comments

LONDON & SEATTLE--(BUSINESS WIRE)-- #BRIMOCHOL--Tenpoint Therapeutics Ltd. announces FDA acceptance of New Drug Application for BRIMOCHOL™ PF for the treatment of presbyopia

← Inexpensive HIV Med Improves Vision in Diabetic Eye Disease

VIDEO: OCU410 gene therapy for geographic atrophy safe in early data →

Post navigation